Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Theralase Technologies Inc (TLTFF)

Theralase Technologies Inc (TLTFF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus Newsfile - Tue Jun 30, 3:44PM CDT

Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...

TLT.VN : 0.270 (-3.57%)
TLTFF : 0.1938 (-3.10%)
Theralase(R) Lists Warrants on the TSXV Newsfile - Wed Jun 3, 6:14AM CDT

Toronto, Ontario--(Newsfile Corp. - June 3, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...

TLT.VN : 0.270 (-3.57%)
TLTFF : 0.1938 (-3.10%)
Theralase(R) Releases Q1 2026 Financial Statements Newsfile - Fri May 29, 4:06PM CDT

Theralase(R) Provides an Update on its Phase II Bladder Cancer Clinical StudyToronto, Ontario--(Newsfile Corp. - May 29, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®"...

TLT.VN : 0.270 (-3.57%)
TLTFF : 0.1938 (-3.10%)
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update Newsfile - Mon May 4, 4:22PM CDT

Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...

TLT.VN : 0.270 (-3.57%)
TLTFF : 0.1938 (-3.10%)
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study Newsfile - Mon Apr 13, 6:16AM CDT

Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...

TLT.VN : 0.270 (-3.57%)
TLTFF : 0.1938 (-3.10%)
Theralase(R) Closes $CAN 2.66 Million Financing Newsfile - Fri Apr 10, 6:06AM CDT

Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...

TLT.VN : 0.270 (-3.57%)
TLTFF : 0.1938 (-3.10%)
Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus Newsfile - Tue Mar 17, 6:16AM CDT

Toronto, Ontario--(Newsfile Corp. - March 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company, dedicated to...

TLT.VN : 0.270 (-3.57%)
TLTFF : 0.1938 (-3.10%)
Theralase(R) Closes $1.1 M Non-Brokered Private Placement Newsfile - Tue Mar 10, 6:16AM CDT

Toronto, Ontario--(Newsfile Corp. - March 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...

TLT.VN : 0.270 (-3.57%)
TLTFF : 0.1938 (-3.10%)
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer Newsfile - Mon Mar 9, 6:16AM CDT

Toronto, Ontario--(Newsfile Corp. - March 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...

TLT.VN : 0.270 (-3.57%)
TLTFF : 0.1938 (-3.10%)
Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy Newsfile - Mon Mar 2, 6:04AM CST

Theralase(R) Demonstrates Additive Anti-Cancer Effect in Bladder Cancer In-Vitro Model when Light-Activated Ruvidar(R) is Combined with InterferonToronto, Ontario--(Newsfile Corp. - March 2, 2026) - Theralase®...

TLT.VN : 0.270 (-3.57%)
TLTFF : 0.1938 (-3.10%)

Barchart Exclusives

Nike’s Dividend Yield Is Near Record Highs, But That’s Not a Good Enough Reason to Buy NKE Stock Barchart - Wed Jul 8, 6:30PM CDT
Nike's dividend yield is nearly 3.8%, which is near the record highs we saw last month. That, however, does not make the stock a buy. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.